Wed Oct 16 11:10:00 UTC 2024: ## 23andMe Faces Uncertain Future Amidst Data Breach and Potential Sale

**San Francisco, CA** – Genetic testing company 23andMe is facing a turbulent period following a data breach in late 2023 and a full board resignation. The company, which collects highly personal DNA data from its customers, is now facing an uncertain future, with many customers concerned about the security of their genetic information.

CEO Anne Wojcicki’s recent announcement regarding a potential company takeover has further fueled these concerns. While she has since clarified that she is not considering third-party proposals and intends to take the company private, many users remain wary.

Cybersecurity experts, including Eva Galperin from the Electronic Frontier Foundation (EFF), are urging 23andMe users to delete their accounts and data, highlighting the potential risks associated with data breaches and unauthorized access to sensitive genetic information.

While experts agree that the data is no more vulnerable today than it has been in the past, they emphasize the importance of reviewing privacy policies and understanding how data is being shared.

“It’s not necessarily unique to where 23andMe is right now, but one’s genetic information reveals a lot about their family’s and their own health,” said genetic privacy expert Anya Prince. “If someone had access to that information, they could learn something about your health.”

23andMe’s research program, which utilizes de-identified genetic information from customers, has raised concerns about data sharing with third parties, including pharmaceutical companies.

While the Genetic Information Nondiscrimination Act (GINA) protects individuals from discrimination by health insurance companies based on genetic information, experts warn about potential misuse by other entities, particularly in the future.

“The concern is not about what people could find out today, but in the future,” said Jason Kelley, activism director at EFF. “Having access to this kind of information could give someone an enormous amount of intelligence about groups of people and potentially individuals.”

23andMe customers have the option to delete their accounts and data through a straightforward automated process. However, data that has already been shared for research purposes cannot be retracted.

Experts advise users to carefully consider the risks associated with sharing sensitive genetic information with any third party. As awareness about data privacy and security grows, individuals are becoming more cautious about the implications of sharing their personal data.

23andMe’s stock price has plummeted since 2021, closing at 29 cents on Monday. The company’s future remains uncertain, with customer trust and data security at the forefront of concerns.

Read More